ArticleCornea2026
Clinical Outcomes of Rose Bengal Photodynamic Therapy for Severe Infectious Keratitis.
Article in Cornea, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the clinical outcomes, microbiological profile, and efficacy of Rose Bengal photodynamic therapy (RB-PDT) as adjuvant treatment in patients with severe infectious keratitis (IK).
methodsProspective, noncontrolled, interventional study. Severe IK was defined as meeting ≥2 of the following: central ulcer, infiltrate ≥3 mm, presence of corneal melting or hypopyon, and lack of clinical improvement with conventional medical treatment. Clinical success was defined as avoiding a therapeutic keratoplasty (TPK).
resultsA total of 21 eyes from 21 patients underwent RB-PDT. Clinical success was achieved in 61.9%. The mean follow-up was 9 ± 3.33 months (range: 4-15). Cultured samples were positive for 27 total microorganisms, including Fusarium spp (n = 12, 44.44%), S. epidermidis (n = 4, 14.81%), Acanthamoeba (n = 2, 7.40%), Pseudomonas spp (n = 3, 11.11%), and others. Cultured samples were grouped into bacterial (44.44%), fungal (48.14%), and polymicrobial (if cultured for multiple microorganisms, 28.57%) categories for analysis. Corneal melting (57.14%), hypopyon (57.14%), and fung-ball (38.1%) were present at the initial visit. The mean time from onset to clinical success was 89.69 ± 56.59 days. In cases of clinical success, the mean time from RB-PDT to clinical success was 46.69 ± 19.47 days. There was a total of 16 additional interventions, including evisceration (2), optical penetrating keratoplasty (5), conjunctival flap (3), amniotic membrane transplant (1), and topical losartan therapy (5). Clinical variables associated with clinical failure included diabetes and fung-ball at presentation.
conclusionsRB-PDT shows potential as an adjuvant therapy for managing severe infectious keratitis. TPK was avoided in 61.9% of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.